Last reviewed · How we verify
Recombinant human arylsulfatase A
At a glance
| Generic name | Recombinant human arylsulfatase A |
|---|---|
| Also known as | HGT-1110, rhASA |
| Sponsor | Shire |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation (PHASE2)
- RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) (PHASE3)
- A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy (PHASE2)
- An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy (PHASE1, PHASE2)
- Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) (PHASE1)
- RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) (PHASE1, PHASE2)
- CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) (PHASE2, PHASE3)
- A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant human arylsulfatase A CI brief — competitive landscape report
- Recombinant human arylsulfatase A updates RSS · CI watch RSS
- Shire portfolio CI